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Abstract
Any new drug or biological product undergoes rigorous testing in animals and humans for
review by the United States Food and Drug Administration (FDA) before it becomes
available for human use. A sponsor files an investigational new drug (IND) application with
the FDA with supporting animal data, after which testing is continued with humans. There is
sufficient guidance from the FDA on new small molecules and biological products as to
which preclinical studies are to be conducted. Synthetic peptides present a unique scenario in
which a case-by-case approach is needed for the conduct of preclinical studies. For peptides
containing components that are already tested for genotoxicity, it is unnecessary to reevaluate
them. If such information can be shared with sponsors ahead of the IND application, it can
save time and money. There is no research that evaluated the FDA’s views on pre-IND
consultation. Therefore, through a 10-item questionnaire, FDA reviewers’ perceptions on
pre-IND consultation, particularly synthetic peptides, were examined. Only four CDER FDA
reviewers responded. Three reviewers stated willingness to provide advice to the sponsor
through pre-IND discussion and to consult supervisory project managers. Two reviewers
agreed that synthetic peptides are to be considered individually for genotoxicity purposes and
that pre-testing consultation should be sought. Future research from a larger sample may
provide insights on the perceptions of the FDA. Information gleaned from previously
approved peptides, however, indicates that there is a wide variability in the type of preclinical studies submitted with an NDA (New Drug Application) before progressing to firstin-human studies. However, the routinely submitted studies were single and repeat dose
toxicity, genotoxicity, carcinogenicity, reproductive and developmental toxicity, and often
studies for impurities.
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PRECLINICAL TESTING OF SYNTHETIC PEPTIDES
Chapter 1: Introduction
In the United States, the Food and Drug Administration (FDA) is the institutional
body responsible for “protecting the public health by assuring the safety, effectiveness,
quality, and security of human and veterinary drugs, vaccines and other biological products,
and medical devices” (U. S. Food and Drug Administration, 2018d). Any drug or biological
product that is developed for treatment or diagnostic purpose undergoes a rigorous review
process by the FDA before it becomes approved for clinical use. A pharmaceutical firm that
develops a drug is termed its sponsor. A recent report by the Tufts Center for the Study of
Drug Development (2014), using the drug development data from 1995–2013 (from 10
firms), indicated that approximately $2.6 billion is spent for each FDA-approved medicine
that reaches the US market and that the process from synthesis to approval takes an average
of 10 years. Out of 1,442 investigational compounds identified in the research, only 7.1%
were approved, while 80.3% had been discontinued and 12.6% were still active by the end of
2013. Of note, the research showed that a significant amount of time (nearly 31 months) and
money (nearly 31% of the total expenditure) is spent during the preclinical phase, that is, the
phase before the drug is tested in humans (Tufts Center for the Study of Drug Development,
2014).
Peptides are a unique class of drugs that structurally fall between small molecules and
proteins and possess unique advantages of high specificity and low toxicity. The first peptide,
insulin, was discovered in 1920, and more than 60 peptides have been approved for human
use as of 2017 (Lau & Dunn, 2017). Technological advancements in the identification of new
receptors and targets involved in disease pathogenesis have paved the way for increased
research on peptides for management of disease. However, certain intrinsic properties such as
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metabolic instability and the need for parenteral route of administration are major hurdles for
peptide development. Chemically synthesized peptides overcome these challenges by the use
of non-natural amino acids to improve the metabolic stability, or chemicals such as
polyethylene glycols, are used to enhance membrane transportation (Groß, Hashimoto, Sticht,
& Eichler, 2015). The most challenging phase for peptide development is the preclinical
phase. As peptides do not reach the cellular targets by diffusion like small molecules and
exert effects by binding to a cell surface receptor, the determination of their pharmacological
and pharmacokinetic parameters through in vitro and in vivo assays is challenging. (Uhlig,
2014). Although there are guidance documents for sponsors on recommendations for proteins
(ICH S6) and small novel chemical entities (NCEs; ICH S1-S5, S7-S8, ICH M3), guidance
specific to peptides is limited. Pre-investigational new drug interactions between sponsors
and the FDA may help clarify regulatory issues. Given limited literature on the regulation of
peptide drug products, this study intended to assess FDA opinions related to the preclinical
testing of synthetic peptides.
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Chapter 2: Background
Overview of Preclinical Studies Submitted with IND
An investigational new drug (IND) typically consists of non-clinical and clinical
components. Key non-clinical components include the preclinical data from the animal
pharmacology and toxicology studies, and chemistry, manufacturing, and controls of the
investigational drug. Clinical components contain the protocols for the proposed human
studies and summaries of previous human experience, if any. Detailed information on the
IND application is available in the 21CFR (Code of Federal Regulation) Part 312.
Typically, non-clinical studies are conducted in order to
•

evaluate the mode of action of the treatment,

•

identify the safe starting dose and dose escalations for the first-in-human
studies,

•

determine toxic doses and potential target organs,

•

assess whether the toxicities are reversible, and, finally,

•

determine which safety parameters are to be monitored in human studies
(International Conference on Harmonization, 1997).

The nonclinical studies submitted to an IND can be broadly categorized as
pharmacokinetics, pharmacology, and animal toxicity studies. In vivo testing includes
relevant animal models to estimate the lowest dose for therapeutic efficacy (Maralee, 2014).
Other non-clinical safety studies include single and repeated dose toxicity studies in two
species, reproductive toxicity studies, genotoxicity studies, and studies for special safety
concerns such as immunogenicity and carcinogenicity (International Conference on
Harmonization, 2009). An overview of the preclinical studies typically conducted as a part of
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drug development program is presented in the Table 1. The specific objectives of each type of
non-clinical study and a few examples of each type of study are presented in Appendix A.
Table 1
List of Safety Studies
Type of Safety Study
Acute Toxicity

Timing of the Study
Prior to Phase 1, 2 and 3

Sub-acute/Sub-chronic Toxicity

In parallel with Phase I clinical studies

Chronic Toxicity
Safety Pharmacology
Genotoxicity

Concurrently with Phase III clinical trials
Prior to Phase 1
In vitro: Prior to Phase 1
In vivo: Prior to Phase 2

Developmental and Reproductive
Toxicity

Carcinogenicity

Prior to Phase 3
Phase 1 clinical studies (in male volunteers) may start even
without the development/reproductive toxicity data, if the
treatment does not indicate any testicular damage in safety
studies of 2 to 4 weeks’ duration
During Phase II and III of clinical development.
Usually required for drugs intended for continuous treatment
for 6 months or more duration

Note. From “Non-clinical studies in the process of new drug development: Part II: Good laboratory practice,
metabolism, pharmacokinetics, safety and dose translation to clinical studies” by E. L. Andrade, A. F. Bento,
J.Cavalli, S. K. Oliveira, R. C. Schwanke, J. M. Siqueira, C. S. Freitas, R. Marcon, and J. B. Calixto, 2016,
Brazilian Journal of Medical and Biological Research, 49, p7–17;
“Chapter 9: Animal use in toxicity studies”, The ethics of research involving animals. p. 155–167. London:
Nuffield Council on Bioethics.

Review Process at FDA
Within the FDA, there are two centers for reviewing an IND application for a
therapeutic product: the Center for Drug Evaluation and Research (CDER) and the Center for
Biological Evaluation and Research (CBER). A sponsor will submit the IND to CDER or
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CBER, depending on the scope of the regulatory supervision of these bodies. Small
molecules are covered majorly by the CDER while biological products are primarily
reviewed by the CBER (U. S. Food and Drug Administration, 2018b). In 2003, the FDA
transferred the regulatory responsibilities for some therapeutic biological products to CDER.
These products include monoclonal antibodies and proteins intended for therapeutic use, such
as cytokines, enzymes, and other novel proteins, immunomodulators, and targeted biological
treatments that alter the production of hematopoietic cells (U. S. Food and Drug
Administration, 2018f). CDER/CBER reviews the information with an IND and accepts or
rejects the IND (U. S. Food and Drug Administration, 2017d). In 2016, CDER received
overall 1669 drug and novel biologic INDs (U. S. Food and Drug Administration, 2017c).
The CDER Offices of New Drugs consists of six Offices and a total of 19 review
divisions that undertake the IND reviews. INDs are currently assigned to one review division
from the following (U. S. Food and Drug Administration, 2018a):
•

Office of Drug Evaluation I – Division of Cardiovascular and Renal Products;
Division of Neurology Products; Division of Psychiatric Products.

•

Office of Drug Evaluation II – Division of Metabolic and Endocrineo Products;
Division of Pulmonary, Allergy, and Rheumatology Products; Division of Anesthesia,
Analgesia, and Addiction Products.

•

Office of Drug Evaluation III – Division of Gastroenterology and Inborn Errors
Products; Division of Bone, Reproductive, and Urologic Products; Division of
Dermatology and Dental Products.
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Office of Drug Evaluation IV – Division of Nonprescription Clinical Evaluation;
Division of Medical Imaging Products; Division of Pediatric and Maternal Health
Products.

•

Office of Antimicrobial Products (OAP) – Division of Anti-Infective Products;
Division of Antiviral Products; Division of Transplant and Ophthalmology Products.

•

Office of Hematology and Oncology Products (OHOP)– Division of Oncology
Products (one and two); Division of Hematology Products; Division of Hematology
Oncology Toxicology.

FDA Review Process in Brief
When an IND application is received, the division director appoints the crossdiscipline team leader based on the content of application; most often the choice is a medical
officer, who is also responsible for the review of clinical section (U. S. Food and Drug
Administration, n.d.). The other review team members are
•

project managers, who are the primary contacts with the sponsor and who prepare the
review plan, coordinate the review team activities, monitor the review status,
maintain up-to-date information on milestones, and assure a timely review;

•

a medical officer, who reviews clinical studies;

•

a pharmacology/toxicology specialist, who reviews all nonclinical (animal) studies;

•

statisticians, who review protocols and the statistical analysis plan;

•

clinical pharmacology/biopharmaceutics reviewers, who evaluate pharmacokinetic
and pharmacodynamics of the study drug; and

•

chemists, who evaluate drug chemistry, manufacturing and controls, stability profile,
and other chemistry issues (U. S. Food and Drug Administration, 2015).
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FDA Guidance for Sponsors
The FDA recommends that sponsors follow the requirements in guidance documents
published by the International Council for Harmonization of Technical Requirements for
Pharmaceuticals for Human Use (ICH). These documents can help formulate essential
studies to be submitted with an IND to gain approval for first-in-human trials. The
requirements for the conduct of each type on non-clinical studies are listed in specific ICH
guidance documents, listed in Table 2, which also extends further (U. S. Food and Drugs
Administration, 2018e; International Conference on Harmonization, 2009)
Table 2
List of ICH Guidance Documents by Type of Non-clinical Study

Non-clinical Tests – Related ICH guidance
Pharmacokinetic Studies:

ICH guidance document

Guidance on toxicokinetics: Assessment of
systemic exposure in toxicity studies

ICH S3A

Guidance on pharmacokinetics: repeated
dose tissue distribution studies
Chronic Toxicity Studies:

ICH S3B

Guidance on duration of chronic toxicity
testing in animals (rodents and non-rodent
toxicity testing)
Genotoxicity Studies:

ICH S4

Genotoxicity testing and data interpretation
for pharmaceuticals intended for human use

ICH S2 (R1)

Guidance on assessment and control of DNA ICH M7
reactive (mutagenic) impurities in
pharmaceuticals to limit potential
carcinogenic risk
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Table 2 continued

Carcinogenicity Studies:
Guidance on
• Need for carcinogenicity and
• Testing for carcinogenicity of
Pharmaceuticals
• Dose selection for carcinogenicity
studies of pharmaceuticals

ICH S1A, S1B, S1C (R2)

Safety Pharmacology Studies
Guidance on
• Safety pharmacology studies for
human pharmaceuticals
• Nonclinical evaluation of the
potential for delayed ventricular
repolarization (QT interval
prolongation) by human
pharmaceuticals
Reproductive Toxicity Studies

ICH S7A, S7B

ICH S5
Guideline on Detection of Toxicity to
Reproduction for Human Pharmaceuticals
Immunotoxicity Studies

ICH S8

Guidance on immunotoxicity studies for
human pharmaceuticals
Note. All guidance documents were developed within the Safety Implementation Working Group of the
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

There are multiple opportunities for the drug sponsor to meet with the FDA team in
the drug developmental process. Such interactions can help sponsors not only to reduce
chances of IND rejection but also to learn of current issues. One such opportunity is the preIND meetings. These can reduce time to market in many ways, such as by identifying and
avoiding unnecessary studies, confirming designs of the needed studies, minimizing costs,
and allowing early interactions/negotiations with the FDA. The pre-IND meeting request
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must be submitted at least four weeks earlier than the scheduled date and along with a preIND package containing all necessary background information and the list of questions that
the sponsor requires the FDA to answer. Pre-IND meetings are useful for sponsors for studies
with scientific or regulatory issues related to clinical trial design, toxicity, unique metabolites,
non-standard or novel formulations, dosing limitations, species suitability, and
immunogenicity (National Heart, Lung, and Blood Institute, 2013). There is a specific FDA
guidance document that talks about the conduct of formal meetings (U. S. Food and Drug
Administration, 2017b).
Prior to a pre-IND meeting, the sponsor may also have an informal meeting with the
FDA team, through a pre-pre-IND teleconference. This will not reduce the necessity of a preIND meeting but can help the sponsor get possible solutions related to preclinical issues. For
example, the selection of animal model for the preclinical study can be discussed (Feigal et
al., 2012).
Peptides and Synthetic Peptides
Peptides have been a unique, rapidly growing class of treatments since the advent of
insulin in the early 1920s (Banting, Best, Collip, Campbell, & Fletcher, 1922). Across the
United States, Europe, and Japan, more than 60 peptide drugs were approved before 2017,
and more than 150 are under active clinical development (Lau & Dunn, 2017). Peptides have
been recognized as promising therapeutic agents for the treatment of various conditions such
as cancer, and, metabolic, infectious, or cardiovascular diseases (Vlieghe, Lisowski, Martinez,
& Khrestchatisky, 2010; Lau & Dunn, 2017). Special advantages that peptides show over
other drugs include being highly versatile, target-specific, less toxic, and able to act on a
wide variety of targets (Fosgerau & Hoffmann, 2015; Vlieghe et al., 2010), which are directly
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responsible for greater success rate than small molecules (approval rate of around 20%
versus 10%; Lax, 2013; Uhlig et al., 2014). The list of FDA approved peptides is presented in
Appendix A (Usmani et al., 2017).
Initially, life-saving peptides such as insulin and ACTH were isolated from natural
sources. The feasibility of chemical synthesis of peptides in 1950s enabled the introduction
of synthetic oxytocin and vasopressin. Further, the recent technological developments in the
genomic era helped in identification and characterization of peptide hormone receptors, and
novel ligands for these receptors are being actively explored (Feigal et al., 2012).
The intrinsic limitations for peptides include metabolic instability, that is, the inability
to withstand 600 proteases in the human body (Lopez-Otin & Matrisian, 2007) and restriction
to the parenteral route of administration. Chemically synthesized peptides can overcome both
of these challenges by incorporating additional entities, such as non-natural amino acids, to
improve the metabolic stability, or other chemical entities, such as polyethylene glycols, to
enhance membrane transportation (Groß et al., 2015).
During the drug developmental process, the most challenging phase for peptides is
the preclinical phase. Conventional smaller therapeutic molecules reach their cellular targets
by diffusion, but peptides enter cells through the surface receptors, and therefore,
determining their in vitro and in vivo pharmacology from immunological assays becomes
challenging (Uhlig et al., 2014). For example, 4F peptides have demonstrated potent antiinflammatory, anti-oxidant, and atheroprotective effects in preclinical models of apoE null
mice and in human aortic cell cultures but failed to show the same effects in human trials.
This could be attributed to the differences in the composition of lipid-associated proteins
between humans and mice (Recio, Maione, Iqbal, Mascolo, & De Feo, 2016). Peptide-based
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therapeutics have a higher chance of clearing the early clinical trials than other drugs, once
they overcome the IND hurdles (Otvos, 2014).
Importance of FDA guidance on preclinical studies of synthetic peptides.
Peptides fall under a distinct category of treatments, and there is no FDA guidance specific to
the preclinical testing of peptides. The current biopharmaceutical guidance documents are
used to determine the recommended battery of essential preclinical tests. The ICH S6
consists of recommendations for biological therapeutics while other documents, such as ICH
S1-S5, S7-S8, ICH M3, are for smaller molecule drugs. The areas of uncertainty for peptide
drug development, for which a pre-IND consultation would greatly help, are described below.
Species selection. Typically, it is recommended that toxicology testing be performed
in two different species; the most commonly used are rats and dogs (Kingham, Klasa, &
Carver, 2010). As biologics show tissue-specific activity, conducting such studies in a
pharmacologically irrelevant species will be inappropriate. In those cases, sponsors may
utilize homologous proteins or transgenic animals that express human receptor or other
animal models (Kingham et al., 2010).
Immunogenicity is another factor for species selection, particularly for vaccine
peptides. Sponsors should always note that animal data are not truly indicative of human
immune response. Elevated antibody production during repeat-dose toxicity studies may not
necessarily be the rationale for the termination of the preclinical studies unless observed in a
large proportion of animals (Kingham et al., 2010).
Genotoxicity. Previously, in a typical small molecule preclinical testing approach,
genotoxicity testing was often conducted. However, recent regulatory guidance documents
have been amended and now state that genotoxicity testing is not necessary with biological
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products. This is because they are not directly associated with any known genetic toxicity
risk (International Conference on Harmonization, 2011). But in instances where the biologic
product has any molecule with such risk, genetic toxicity testing might be needed
(Vugmeyster, Xu, Theil, Khawli, & Leach, 2012).
Synthetic peptides present a special scenario for genotoxicity testing. If the test
peptide contains exclusively natural amino acids, testing may not be necessary. Also, testing
may not be necessary for peptides that contain already tested non-natural amino acids, linkers,
and non-linker components. However, if such peptides have been modified for better cellular
absorption, the in vivo genotoxicity testing may be necessary. Linkers that can be potentially
mutagenic impurities need to be evaluated as per ICH M7 (Thybaud et al., 2016). Testing for
such process-related impurities is the key difference between the biotechnologically-derived
and chemically-synthesized peptides (Heidel & Page, 2010).
Pre-IND and “pre-pre-IND” meetings are the best opportunities for the sponsors to
discuss any preclinical issues with the FDA before IND filing. These meetings can help
sponsors provide adequate information with the IND and avoid clinical holds from the FDA
(Feigal et al., 2012).
Purpose of the Study
Although many published sources recommended that pre-IND consultation would be
beneficial for sponsors to aid the therapeutic biologic development process, there is no
research that captured the FDA’s perspective on this issue. Synthetic peptides have been a
key research area in recent years with several preclinical issues, as highlighted in previous
sections. Any direct evidence captured from the FDA reviewers’ viewpoint could further help
sponsors plan better for the consultation program. Hence, this study was conducted to assess
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FDA opinions related to synthetic peptides in two ways. First, a survey was conducted to
understand the FDA reviewers’ responses to the questions related to the conduct of
preclinical studies, with some specifically on synthetic peptides. Second, FDA
documentation was reviewed to summarize the non-clinical studies from the recently
approved synthetic peptides.
Research Questions
The first part of the study aimed to address the following through this survey:
•

What are the preclinical toxicology requirements for synthetic peptides?

•

How can researchers obtain input?

•

What suggestions might FDA reviewers have to resolve this question?

The second part of the study aimed to address the following:
•

What non-clinical studies have been submitted with INDs for recently
approved synthetic peptides?

13
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Chapter 3: Methods
Part 1 – Online Survey of FDA Reviewers
The study used an e-mail survey with a 10-item multiple-choice questionnaire. As this
research focused on understanding the perceptions of the FDA on regulatory issues of
synthetic peptides, FDA reviewers were considered the targeted study population. In the
questionnaire, the first three items captured the background profile and experience of the
FDA employee. The next seven items included specific questions related to the synthetic
peptides. Appendix B contains the questionnaire. Space was left at the end of the
questionnaire for free text suggestions or feedback from survey participants.
The survey questions were uploaded into the Google survey tool, Google forms, and
the link was saved by the researcher. After receiving the approval of the University Human
Subjects Review Committee at Eastern Michigan University (Appendix C), the Google form
link with the survey questions was forwarded to one of the FDA employees. This employee
later directed it individually to other FDA employees, from his contacts in the FDA, via their
official e-mail IDs. Overall, the questionnaire was forwarded to approximately eighty FDA
reviewing or supervisory pharmacologists.
Part 2 – Review of Previously Submitted Non-Clinical Studies
In the second part of the study, data from two recent review articles by Vlieghe and
colleagues (2010), and Lau and Dunn (2017) that contained the names of approved synthetic
peptides across the world were reviewed. In the review article by Vlieghe et al. (2010) the
authors tabulated the information on peptides approved in the US, Europe, and Japan, with
specific details on peptide length (number of amino acids) and sequence, and the specific
indications. In the review article by Lau and Dunn (2017), the authors also summarized the
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status in the US, Europe, and Japan on approved peptides, as well as their route of
administration and targeting receptors in the supplementary table of the published paper.
Each peptide identified from the two articles was then checked for US approval dates,
number of amino acids, manufacturing process, and whether synthetic or not, from the FDA
website (U. S. Food and Drug Administration, 2018c) and the Drug Bank online database
(DrugBank, 2018). For the current research, any polymer with 40 or fewer amino acids was
considered a peptide, as adopted by the FDA. Of them, only synthetic peptides with 40 or
fewer amino acids approved by FDA composed the peptide set of interest for this study.
For synthetic peptide drugs approved between 2007 and 2017, the non-clinical
pharmacology review information was obtained from the FDA website (U. S. Food and Drug
Administration, 2018c). From each PDF document, information with respect to non-clinical
studies was extracted and summarized.
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Chapter 4: Results
Part 1 – Online Survey of FDA Reviewers
Of the 80 recipients of the questionnaire email, only four FDA reviewers responded.
The survey responses are presented in Table 3. Out of four, three respondents were reviewing
pharmacologists and one was a supervisory reviewer. All of them were reviewers at the
CDER. Experience at the FDA was more than 10 years for three respondents, while a single
respondent’s experience was between 6 and 10 years.
Most reviewers were willing to provide advice to sponsors prior to submission but
only with a pre-IND meeting request, whereas one reviewer was against providing any
informal advice. Two preferred face-to-face conversation as the best way of communication
with sponsors regarding any advice. Three of the four respondents recommended contacting
the supervisory project manager for advice. Two respondents agreed that pre-testing
consultation was necessary for synthetic peptides and that each compound should be treated
separately. Also, two reviewers suggested that more than two months’ time should be allowed
for receiving input from the FDA before beginning toxicology tests of synthetic peptides. All
of the reviewers agreed that pharmacological differences between human and animal models
are a concern for selection of species for toxicological studies. In that case, two reviewers
recommended pre-testing consultation with FDA, while two stated that animals should
exhibit the same pharmacology as humans for toxicity testing. Finally, two reviewers claimed
to have had personal experiences in dealing with issues pre-IND, but not as the specific ones
mentioned in the survey. One reviewer had an experience similar to those in the
questionnaire.
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Table 3
Responses to the Survey
Question

n

%

Reviewing Pharmacologist

3

75%

Supervisory Pharmacologist

1

25%

4

100%

6 to 10

1

25%

Greater than 10

3

75%

Yes, but a pre-IND meeting request and supporting documentation must be
submitted

3

75%

No, an active IND must be on file

1

25%

Teleconference to discuss previously submitted materials

1

25%

Face-to-face meeting to discuss previously submitted materials

2

50%

Email replies from a reviewer to very specific questions

1

25%

The supervisory project manager

3

75%

Any divisional project manager

1

25%

To be handled like a biologic product

1

25%

To vary by compound. Pre-testing consultation should be sought

2

50%

Unknown

1

25%

Yes, the animal model used for toxicity testing must exhibit the same
pharmacology as that expected in humans

2

50%

Pre-testing consultation with the Review Division should be sought

2

50%

1. Position at FDA

2. Review Center
CDER
3. Years at FDA

4. Are you willing/able to provide informal advice to sponsors prior to
submission of an IND?

5. The best way to obtain advice prior to IND submission is via

6. The appropriate contact to request pre-IND advice is

7. Synthetic peptides should be considered, for genotoxicity purposes

8. If human synthetic peptides or biologics do not show the same
pharmacology in animal models as they do in human tissue cultures, is this a
concern for selection of species for toxicology testing?
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Table 3 continued
Question

n

%

1 month

1

25%

2 months

1

25%

More than 2 months

2

50%

Yes for issues pre-IND, but not those specific ones mentioned here.

2

50%

Yes

1

25%

No

1

25%

9. If pre-testing consultation is required before beginning toxicology test,
how much time should be the sponsor build into their planning to allow
appropriate input from agency?

10. Have you had personal experience dealing with issues like those
mentioned in this survey?

Part 2 – Review of Previously Submitted Non-Clinical Studies
Out of more than 60 approved peptide drugs identified from the two papers, the final
set included 41 peptides that were chemically synthesized, approved by the FDA, and had 40
or fewer amino acids. These peptides are listed in Table 4.
Table 4
FDA-Approved Synthetic Peptides

1
2
3

Corticotropin
Lypressin
Tetracosactide

FDA
approval
year
1950
1961
1970

4

Desmopressin

1978

9

5

Oxytocin

1980

9

6

Saralasin acetate

1981

8

7

Gonadorelin

1982

10

8

Enalapril
Calcitonin
salmon
Calcitonin
(human)

1985

3

1986

32

1986

32

S. No

9
10

Synthetic
peptide drug

Number
of amino
acids
39
9
24

Indication

Status

Diagnosis - adrenocortical insufficiency
Central diabetes insipidus, Cushing’s syndrome
Diagnosis - adrenocortical insufficiency
Central diabetes insipidus, nocturnal enuresis,
nocturia, and stoppage of bleeding or hemorrhage in
haemophilia A patients
Initiation or improvement of uterine contractions, and
control postpartum hemorrhage
Hypertension
For evaluating gonadotropes of the anterior pituitary
and residual gonadotropic function of the pituitary
following therapy
Hypertension
Postmenopausal osteoporosis, Paget’s disease,
hypercalcaemia
Postmenopausal osteoporosis, Paget’s disease,
hypercalcaemia

Discontinued
Discontinued
Prescription
Prescription
Prescription
Discontinued
Discontinued
Prescription
Prescription
Discontinued
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Table 4 continued
S. No
11

Synthetic
peptide drug
Lisinopril

FDA
approval
year

Number
of amino
acids

1987

3

Acute myocardial infarction, heart failure,
hypertension

Prescription

1988

8

Acromegaly, neuroendocrine tumors

Prescription

1989

10

Advanced prostate cancer, breast cancer
Central precocious puberty, endometriosis, uterine
fibroids, ovarian stimulation in in vitro fecundation
Advanced prostate cancer, central precocious puberty

Prescription

Relapsing-remitting multiple sclerosis

Prescription

13

Octreotide
Acetate
Goserelin

14

Nafarelin

1990

10

15

Histrelin

1991

16

Glatiramer

1996

9
Random
mixture

17

Eptifibatide

1998

7

18

Ganirelix

1999

10

19

Triptorelin

2000

10

20

Cetrorelix

2000

10

21

Bivalirudin

2000

20

12

23
24
25
26
27
28
29
30
31
32

Leuprolide
acetate
Abarelix
Enfuvirtide
Ziconotide
Pramlintide
Exenatide
Lanreotide
Degarelix
Liraglutide
Icatibant
Lucinactant

33

22

2002

9

2003
2003
2004
2005
2005
2007
2008
2010
2011
2012

10
36
25
37
39
8
10
31
10
21

Linaclotide

2012

14

34

Pasireotide

2012

6

35

Carfilzomib

2012

4

36

Etelcalcetide

2017

7

37
38
39
40

Plecanatide
Abaloparatide
Semaglutide
Macimorelin

2017
2017
2017
2017

16
34
31
2

41

Angiotensin II

2017

8

Indication

Acute coronary syndrome, unstable angina undergoing
PCI
Inhibition of premature leutinizing hormone surges in
controlled ovarian hyperstimulation
Advanced prostate cancer, central precocious puberty,
endometriosis, uterine fibroids, ovarian stimulation in
in vitro fecundation
Inhibition of premature LH surges in women
Undergoing controlled ovarian stimulation
Anticoagulant for unstable angina patients undergoing
angioplasty
Advanced prostate cancer, breast cancer, central
precocious puberty
Advanced prostate cancer
AIDS
Severe chronic pain
Type 1 and 2 diabetes
Type 2 diabetes mellitus
Acromegaly, carcinoid syndrome
Advanced prostate cancer
Type 2 diabetes
Hereditary angioedema
Neonatal respiratory distress syndrome
Constipation-dominant irritable bowel syndrome,
chronic idiopathic constipation
Cushing’s disease, specifically for patients not eligible
for pituitary surgery
Progressive multiple myeloma after treatment with
bortezomib and an immunomodulatory agent
Secondary hyperparathyroidism in chronic kidney
disease patients on hemodialysis
Chronic idiopathic constipation
Postmenopausal osteoporosis
Type 2 diabetes mellitus
Diagnosis - adult growth hormone deficiency
Increase blood pressure in patients with sepsis or other
critical conditions

Status

Prescription
Prescription

Prescription
Prescription
Prescription
Prescription
Prescription
Prescription
Discontinued
Prescription
Prescription
Prescription
Prescription
Prescription
Prescription
Prescription
Prescription
Discontinued
Prescription
Prescription
Prescription
Prescription
Prescription
Prescription
Prescription
Prescription
Prescription

Note. From “Synthetic therapeutic peptides: science and market” by P. Vlieghe, V. Lisowski, J. Martinez, and
M. Khrestchatisky, 2010, Drug Discovery Today, 15, p. 40‒56;
“Therapeutic peptides: historical perspectives, current development trends, and future directions” by J. L. Lau
and M. K. Dunn, 2017, Bioorganic & Medicinal Chemistry, 26, p. 2700‒2707;
“Therapeutic peptides” by F. Albercio and H. Kruger, 2012, Future Medicinal Chemistry, 4, p. 1527‒31;
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“2017 FDA peptide harvest” by O. Al Musaimi, D. Al Shaer, D. L. Torre, and F. Albericio, 2018,
Pharmaceuticals (Basel), 11, p. 7.

Among the listed peptides, the 14 that were approved between 2007 and 2017
(lanreotide, degarelix, liraglutide, icatibant, lucinactant, linaclotide, pasireotide, carfilzomib,
etelcalcetide, plecanatide, abaloparatide, semaglutide, macimorelin, and Angiotensin II) were
further researched by an examination of the non-clinical FDA reviews. There was a nonuniform distribution of the FDA approvals over the time period of 2007–2017: three were
approved between 2007–2010, five approved between 2011–2012, and six approved in 2017.
No synthetic peptides were approved in the years 2013–2016. The ideal way to present such
heterogenous non-clinical study data is through tables and a maximum of only four could be
accommodated in one table. Hence, these safety studies submitted with the NDA (New Drug
Application) for these peptides summarized in Tables 5–8 in a chronological order: Table 5
for peptides approved in 2007–2010, Table 6 for those approved in 2011 and 2012 (excluding
lucinactant), and Tables 7 and 8 for those approved in 2017 (three peptides as Part A and
three peptides as Part B). For the majority of these peptides, the following categories of
general toxicology studies were conducted: single-dose toxicity, repeat-dose toxicity,
genotoxicity, carcinogenicity, reproductive and developmental toxicity, and special
toxicology studies.
The series of non-clinical tests for Lucinactant were not included in Tables 5–8, since
the non-clinical tests were very different from all other synthetic peptide drugs considered.
Lucinactant was an intratracheal drug with targeted place of action (lungs) to treat acute
respiratory distress in neonates. The non-clinical program of lucinactant included the
following toxicology studies: single dose in newborn rabbits, 7 days in adult rats, 4 days in
rabbits, 14 days in newborn rabbits, a single dose in premature monkeys, immunogenicity in
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monkeys, and systemic anaphylaxis in guinea pigs, preterm lambs, and fetal rabbits assay.
The drug has been discontinued, however, to support the development of another aerosolized
KL4 surfactant for the same indication by the sponsor (Windtree Therapeutics, 2015).
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Table 5
Safety Studies of Synthetic Peptides Approved Between 2007 and 2010
Single Dose

Lanreotide
Mice, rats (previous*)

Degarelix
Mice, rats, monkeys

Liraglutide
Mice, rats

Repeat Dose
1 week

Rats

2 weeks

Rats, monkeys

Monkey

4 weeks

Rats, monkeys

Mice, rats, monkeys

13 weeks

Rats, mice

Mice, rats, monkeys

Rats

Rats

26 weeks

Rats, dog (previous*)
Rats, dog (new formulation)

52 weeks
24 months

Monkeys
Dog (previous*)

Genetic Toxicology tests
Ames test
In vitro DNA damage
in mammalian cells
In vivo test for genetic
damage
Other genotoxicity tests
Carcinogenicity

S. typhi and E.coli (previous*)

S. typhi and E.coli

S. typhi and E.coli

L5178Y/TK+/- mouse lymphoma cells

Cultured human peripheral lymphocytes

Rat micronucleus tests

Rat micronucleus tests

104 weeks rats, mice

104 weeks rats, mice

104 weeks rats, mice

Rats (previous*), Rats (present)

Rats

Cultured human peripheral lymphocytes
(previous*),
L5178Y/TK+/- mouse lymphoma cells
Mouse micronucleus tests (previous*)
Mutations in tissues of Muta™ Mice

Reproductive toxicology
Segment 1 – Fertility
Dose range finding

Rats, rabbits (previous*)

Rabbits
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Table 5 continued
Lanreotide
Segmental (1/2) reproductive
Segment 2 - teratology

Liraglutide

Rats

Rats

Rats, rabbits (previous*)

Pre- and Post-natal

Rabbits
Rats, rabbits

Development
Other Tests
Local toxicity

Degarelix

Rats

None
Rabbits, monkeys, minipigs

Mechanistic studies
Impurities
Other studies

Note. IND, investigational new drug; NDA, new drug application.
*“Previous” refers to studies submitted with previous IND submission or NDA submissions for the same molecule.

Pigs
For t-cell tumors
4 weeks rat toxicity study
Toxicology studies with exenatide for
comparison
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Table 6
Safety Studies of Synthetic Peptides Approved During 2011–2012
Pasireotide
Mice, rats

Carfilzomib
Rats, Monkeys

5 days

Rats, dog

Monkeys

1 week

Rats

Single Dose

Icatibant
Mice, rats, dog (previous*)

Linaclotide
Rats, monkeys

Repeat Dose

2 weeks

Rats

Rats, monkeys

Mice, rats, dog, monkeys

3 weeks

Rats

4 weeks

Dogs

13 weeks

Rats, dogs

Mice (Common study for
drug and impurities)
Mice, rats, monkeys

Monkey, mice, rats

Monkeys
Rats

26 weeks

Mice

Rats

Rats

39 weeks

Monkeys

Monkeys

Monkeys

Dose Ranging Study

Dogs

Rats, monkey (2 week)

Genetic Toxicology tests
Ames test

S. typhi

In vitro DNA damage
in mammalian cells
In vivo test for genetic
damage
Other genotoxicity tests

Cultured human lymphocytes

Carcinogenicity

None

Rat micronucleus test

S. typhi, E coli

S. typhi

S. Typhi and E. coli

Cultured human lymphocytes

Cultured human lymphocytes

Cultured human lymphocytes

None

Rat micronucleus test

Mouse micronucleus test

104 weeks rats, mice

104 weeks rats,
6 months transgenic mice

No carcinogenicity studies as
per ICH S9

Rats

Rats

None

Reproductive toxicology
Segment 1 – Fertility
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Table 6 continued
Icatibant

Linaclotide

Dose range finding

Segment 3 - Pre- and
Post-natal
Development
Fertility and early
embryonic
Other Tests
Local toxicity

Rats, rabbit (previous*)
Rats

Mice, rats, rabbits

Rats, rabbits

Rats

Rats

Combined with 13-week
toxicity test

In vitro assessment using rat
whole embryo culture

Rabbit

Ocular rabbit, dermal rabbit,
Rabbit/rat IM tolerance
Rat immunotoxicity

In vitro hemolysis test

Impurities

Others

Carfilzomib

Rats, rabbits

(Segment 2)
Segment 2 - teratology

Pasireotide

Hyperimmunization studies
in the rat, dog and
monkey
For two degradants, in mice,
single dose study
Safety qualification of
impurities – IV toxicity test,
Ames test, Chromosome
aberration test

4-week toxicity for
impurities, Ames test for
impurities (also mentioned
above)

Tested in juvenile mice and
juvenile rabbits

Rats, rabbits

4-week toxicity test for
impurities, Ames test for
impurities, Chromosome
aberration test for impurities

Phototoxicity

Note. IND, investigational new drug; NDA, new drug application.
* “Previous” refers to studies submitted with previous IND submission or NDA submissions for the same molecule.

Three-part study to
investigate effect of
proteasome inhibition on
endotoxin challenge in mice
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Table 7
Safety Studies of Synthetic Peptides Approved in 2017 – Part 1
Plecanatide
Mice, monkeys, rats

Abaloparatide
Mice, rats

5 days

Mice, Monkeys (3 days)

Monkeys (3 days)

1 week

Mice, rats (7/14 days)

2 weeks

Rats (7/14 days), monkey

4 weeks

Mice, monkeys

Rats, monkeys

Rats, Dogs

13 weeks

Mice, rats, monkeys

Rats, monkeys

Rats, Dogs

26 weeks

Mice

Rats

Rats, Dogs

39 weeks

Monkeys

Monkeys

Dogs

E.coli, S.typhi

E.coli, S. typhi,

S.typhi and E.coli strains

Single Dose

Etecalcitide
Not conducted

Repeat Dose

Rats, Dogs

Genetic Toxicology tests
Ames test
In vitro DNA damage
in mammalian cells
In vivo test for genetic
damage

L5178Y/TK+/- mouse lymphoma cells

Mouse micronucleus test

Cultured human peripheral
lymphocytes

Mouse micronucleus test

lymphocytes, CHO-K1 cells, Chinese
hamster lung fibroblast (V79) cells
Rat micronucleus test
4 week muta™ mouse test

Other genotoxicity tests
Carcinogenicity

Cultured human peripheral

104 weeks rats, mice

104 weeks rats

Mice

Rats

104 weeks rats,
6 months transgenic mice

Reproductive toxicology
Segment 1 – Fertility

Rats (combined Segment 1, 2)
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Table 7 continued
Plecanatide
Dose range finding
(Segment 2)
Segment 2 - teratology
Pre- and Post-natal
Development

Abaloparatide

Etecalcitide

Mice, rabbits

Rats, rabbits

Mice, rabbits

Rats, rabbits

Mice

Rats

Other Tests

Phototoxicity
Local tolerance – rabbit, rat, monkey

Local toxicity
Juvenile toxicity – mice, single dose, 7

Hemolysis testing blood

days, 14 days, 14 or 13 weeks
Rats (2 weeks, 4 weeks) with unknown
Impurities

Dogs

degradant, standard battery of
genotoxicity for impurities

4 weeks rats for mixture and
impurities, 4 weeks dogs comparing 2
lots, Ames test for sodium isopropyl
sulphate
1.etelcalcetide and structurally related
peptides were evaluated for mutagenic

Mechanistic Studies

activity, 2. For metabolite formation, 3.
L-cysteine for mutagenic potential, and
3 more studies on mutagenicity

Antigenicity

Rabbits (105 days, 136 days)

Note. IND, investigational new drug; NDA, new drug application.
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Table 8
Safety Studies of Synthetic Peptides Approved in 2017 – Part 2
Single Dose

Semaglutide
Mice, rats (previous*)

Macimorelin
Rats, dogs

Repeat Dose

Rats, rabbits (Lit Search)

5 days

Rats, dogs

2 weeks

Mice (previous*), Monkey (previous*)

4 weeks

Rats

13 weeks

Rats
Rats, dogs

Rats, Mice, rats (previous*), monkey
(previous*)

26 weeks

Rats

52 weeks

Monkeys

Dose Ranging Study

8-18 days mice (previous*)
14-25 days (previous*)

Genetic Toxicology tests
Ames test
In vitro DNA damage
in mammalian cells
In vivo test for genetic
damage

Lit Search
E. coli, S. typhi (previous*, present)
Cultured lymphocytes (previous*, present)

Rat micronucleus test

S. typhi (previous*)
L5178Y T/K+/- mouse lymphoma
cells, CHO-K1 cells
Not conducted
DEREK evaluation and MCASE

Other genotoxicity tests

Angiotensin-II
Rats (Lit Search)

evaluation for mutagenicity and
genotoxicity of macimorelin and
impurities
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Table 8 continued
Semaglutide
Rats, mice – 2 year
In vitro GLP-1R activation in rat thyroid C
Carcinogenicity

cell-line
Mice (single dose), Rats (6 weeks dose) for

Macimorelin

Angiotensin-II

Not done as it is single dose
product and the drug

Lit search

pharmacology/toxicology is known

calcitonin levels
Not done as it is single dose
Reproductive toxicology

product and the drug
pharmacology/toxicology is known

Segment 1 – Fertility

Rats
Rats, rabbit, monkey, rats (juvenile toxicity)

Segment 2 -

rabbit (previous*) monkey (previous*),

teratology

juvenile toxicity (previous*, animal not
mentioned)

Pre- and Post-natal
Development

Monkey

Other Tests
Local toxicity

Pigs (previous*), rabbits (previous*)
For embryotoxicity to explore species
specificity

Mechanistic Studies

Conducted whole embryo cultures and
studies in yolk sacs of untreated rats,
monkeys

Note. IND, investigational new drug; NDA, new drug application.

Lit Search
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Chapter 5: Discussion
Part 1 – Online Survey of FDA Reviewers
All of the survey respondents were well experienced, with 6 or more years of
association with the FDA; hence, their thoughts on the survey questions are likely
representative of FDA pharmacologists. Three of four reviewers agreed to provide informal
advice to sponsors through a pre-IND meeting and supporting documentation, highlighting
the significance of such meetings. However, there are no published data that present the
number/proportion of sponsors approaching FDA for a pre-IND meeting advice. Of the four,
only one reviewer agreed that teleconferencing was the best way to obtain advice prior to
IND submission. This may imply that pre-pre-IND meetings, which are usually conducted
through teleconferences, may not be of great value to the sponsors. There are some specific
advantages for a telephonic conference over the face-to-face meeting: Scheduling is easier,
and it is cheaper and more accessible to staff (Yetter, 2005). Two of the four reviewers
recommended that meeting face-to-face is the best way. Face-to-face meetings are preferred
only if such type of interaction is warranted, such as in case of issues concerning scientific,
clinical, and regulatory aspects of the new products (Novak, Ruckman, & Trent, 2009). The
sponsor can request a meeting and the FDA can take a call to provide a written response or
accept a face-to-face meeting based on the questions posed to the FDA (Vaknalli, 2017). A
majority (3/4) of the respondents agreed that the appropriate contact to request pre-IND
advice was the supervisory project manager. The FDA guidance document that consists of
best practices for communications between sponsors and FDA mentioned that the regulatory
project manager is the ideal primary point of contact (U. S. Food and Drug Administration,
2017a).
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In the questions specific to synthetic peptides, two of the four CDER reviewers
suggested that the synthetic peptide evaluation needs to vary by compound and that pretesting consultation should be sought. This is inconsistent with the article by Thybaud et al.
(2016), in which the genotoxicity was described as being assessed only in the presence of
non-natural amino acids or linkers or other components that were not previously assessed for
genotoxicity. As such information gets updated frequently, meeting the FDA before toxicity
testing can greatly help eliminate unnecessary studies and confirm the study design. Related
to the question on the use of animal models for toxicology testing of synthetic peptides, two
reviewers agreed that pre-testing consultation should be sought when human tissue cultures
and animal models do not exhibit same pharmacology. Two reviewers answered by saying
that animal models should show the same pharmacology. In cases when there are
pharmacologically irrelevant species, there are alternatives: performing tests in only the
relevant species, use of transgenic animals, and so on. These can be discussed in a pre-IND
consultation to determine which tests can be performed. To the question on a timeline for
getting input from the agency, three reviewers stated that a period of at least 2 months before
beginning the toxicology tests was reasonable for appropriate input from the FDA. As per the
FDA meeting guidance, pre-IND meetings need to be scheduled within 60 days of the day of
receipt of the sponsor’s meeting request. However, the time limit for sponsors to share the
materials is 30 days before the meeting, which leaves the agency with only 30 days to review
the submitted materials. The minutes will be shared with the sponsor within 30 days (U. S.
Food and Drug Administration, 2017b); only after this time can studies be initiated. So, it
would be ideal for sponsors to allow more than 2 months before toxicity testing. Finally,
three of the four reviewers had personal experiences related to a pre-IND issue, thus
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highlighting the criticality of a pre-IND consultation. Therefore, every sponsor should
seriously consider reaching out to the FDA for a pre-IND consultation program, which can
eventually smooth the approval of IND.
Reasons for a Low Response Rate
This study had a very low response rate of only 5%. Many reasons can be suggested
for this. The FDA is an institutional body with stringent rules. Employees were strictly
prohibited from accessing third party emails; hence, the researcher’s FDA liaison forwarded
the survey link to the personal mail IDs of interested participants. Many times employees
may not have a chance or the time to respond to a survey received on their personal mail
accounts.
There was no possibility for the researcher to personally meet the FDA reviewer staff.
Hence, the seriousness, depth, confidentiality, and purpose of the survey could not be
communicated. If this had been done, it may have slightly improved the response rate.
Based on this researcher’s personal experience of working in pharmaceutical
industries, it appears that FDA responds to emails of pharmaceutical submissions. Meeting in
person is a challenge for companies as well because the FDA insists on having a preappointment booked, and only then will it respond. Being a student, the privilege of having
an email account with a pharmaceutical company was nonexistent, so working for an
academic institute and choosing this concept for study was the major setback that resulted in
a poor response rate.
Part 2 – Review of Previously Submitted Non-Clinical Studies
In the second phase of the research, non-clinical studies submitted for synthetic
peptides approved between 2010 and 2017 were evaluated for patterns in similarities and
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differences. Apart from Lucinactant, a synthetic peptide containing surfactant for use in acute
respiratory distress syndrome in neonates, all studied peptides had similar general safety
studies or evidence submitted with their application for marketing approval. Another general
observation was that no non-clinical studies were conducted for angiotensin-II because this
was an exogenously administered endogenous hormone (human form) with well-known
pharmacological action. Hence, upon the FDA’s request, the sponsor submitted targeted
literature research summaries for all non-clinical safety study categories.
The major species for conducting single dose toxicity for the included synthetic
peptides was the rat, followed by mice and monkeys. Single-dose toxicity was studied in
dogs for only icatibant and macimorelin. No single-dose toxicity study was conducted for
etecalcitide, although no specific explanation was provided in the corresponding
pharmacology review.
Repeat dose toxicity studies were also mostly conducted in rats, mice, and monkeys
similar to single-dose toxicity studies. Preferred species for long-term toxicology studies of
39 or 52 weeks were mammals, including monkeys and dogs. No long-term studies
conducted in rats were submitted. Since macimorelin is a single-dose administration drug for
diagnosis of growth hormone deficiency, general toxicity was conducted in rats and dogs up
to 4 weeks. However, for drugs with long-term administration such as anti-diabetics
liraglutide and semaglutide, safety was studied for a maximum of 52 weeks in monkeys.
For all the synthetic peptides, genotoxicity was tested using the standard battery of
tests including the Ames test, in vitro, and in vivo genetic damage tests. The Ames test was
mainly done on strains of E.coli and S. typhi. For icatibant, pasireotide, and macimorelin, the
Ames test included only S.typhi strains. In vitro DNA damage in mammalian cells was tested
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using assay of L5178Y/TK+/- mouse cells, cultured human peripheral lymphocytes, CHOK1 cells, or V79 cells. Most of the approved peptides included assays involving cultured
human lymphocytes and L5178/TK+/- mouse cells. The more recently approved peptides,
etecalcitide and macimorelin, also included aberration studies conducted in Chinese hamster
ovarian (CHO-K1) cells and Chinese hamster lung fibroblast (V79) cells. An in vivo
genotoxicity test was always conducted for the synthetic peptides (except linaclotide and
macimorelin) and included either a rat or mice micronucleus test. In addition to this standard
battery, in vivo testing was conducted for lanreotide and etecalcitide using a transgenic rodent
model (Muta™Mouse). For macimorelin, genotoxicity was additionally assessed using the in
silico prediction programs, DEREK evaluation and MCASE evaluation. As described in a
2014 review of retrospective FDA approval history starting in 1998, it may not be necessary
to conduct genotoxicity testing for peptides containing natural amino acids (Sawant, Fielden,
& Black, 2014); it depends entirely on the molecular composition of the synthetic peptides
whether genotoxicity evaluation is required or not.
Carcinogenicity studies were submitted for all included synthetic peptides except for
icatibant, carfilzomib, and macimorelin. Carcinogenicity evaluation routinely included
testing for 2-year period in mice, rats, or both. In some cases (pasireotide, etecalcitide),
transgenic mice were also evaluated for a 6-month duration. As carfilzomib is an anti-cancer
pharmaceutical, carcinogenicity testing was not needed as per ICH S9; with the other two
drugs being for intermittent (icatibant) or single (macimorelin) use, carcinogenicity
evaluation was not needed. A more detailed carcinogenicity risk evaluation was conducted
for semaglutide using in vitro thyroid C cell-lines and specific testing for calcitonin levels
predictive of thyroid c-cell tumors (Guesgen et al., 2013). For liraglutide, carcinogenicity
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evaluation included only mechanistic studies for thyroid cell tumors, but the recent molecule
semaglutide involved more thorough evaluation. This indicates the criticality of non-clinical
testing for carcinogenicity evaluation and changing requirements in relation to the
advancements in the field. Thus, consultations with the FDA are crucial.
The developmental and reproductive studies for almost all peptides were conducted
mostly in rodents for all listed synthetic peptides. By specific parameter of toxicity
evaluation, studies analyzing effects on reproduction or fertility (segment 1) were performed
in mice, rats, or both. Teratology or embryo-fetal toxicity (segment 2) and pre- and post-natal
developmental toxicity (segment 3) were also evaluated in mice, rats, and sometimes rabbits.
For only semaglutide, teratology and pre- and post-natal developmental studies were
additionally evaluated in monkeys.
Among all the other non-specific studies conducted, testing for effects of impurities
was the common category of study for six selected peptides. These tests often included
general toxicological evaluation for impurities, mostly for a 4-week duration, and also
genotoxicity evaluation. Apart from impurities, a series of mechanistic studies was often
submitted with the applications that varied from case to case for peptides, depending on the
toxicological findings from the previous non-clinical studies. For example, embryotoxicity
was explored for semaglutide, mutagenicity was explored for etecalcitide, and T-cell
tumorigenic potential was explored for liragutide.
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Chapter 6: Conclusion
Despite having only four survey respondents, the research provided some interesting
findings. Most of the CDER reviewers agreed to share informal advice prior to IND
submission, but only through a pre-IND meeting, and two preferred a face-to-face meeting.
Three of the reviewers agreed that the appropriate contact person for pre-IND advice is a
supervisory project manager, which is not known as per the literature. In the case of synthetic
peptides, pre-IND consultation is reiterated by two reviewers for the genotoxicity testing and
also while having issues with species selection. The second part of the research discovered
great variability for the non-clinical studies submitted with the NDAs of the recently
approved synthetic peptides. Further comprehensive research on variability of each type of
safety study along with route of administration, can help to understand changing regulations
over time. Overall, the research highlights that regular and early interactions with the FDA
will be crucial for an optimistic response from the FDA.
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Appendix A: Supplementary Table
Objectives and Examples of Safety Studies

Type of Study and Description
Acute Toxicity
• To determine preliminary safety of a new molecule by observing the nature and
duration of any adverse events
• To find out short term adverse effects on the administration of the study drug in
a single dose, or in multiple doses during 24 hours in two mammalian species
(one nonrodent) through the clinical route of administration and find the
maximum tolerated dose
• Studies involve steadily increasing the dose (single or a number of consecutive
doses), until adverse effects (such as vomiting and convulsions) indicating that
an maximum tolerated dose has been reached
• Animals are typically observed for 14 days
Examples:
Fixed Dose Procedure (OECDTG 420)
AcuteToxic Class method (OECDTG 423)
Up‐and‐Down Procedure (OECDTG 425)
Acute DermalToxicity (OECDTG 402)
Acute inhalation toxicity
Sub-acute/Sub-chronic Toxicity
• To identify adverse effects that develop over a period of continuous exposure to
the new drug (28 days – sub acute; 90 days - subchronic)
• To identify the most affected organs and determine the doses at which each
effect occurs
• Typically, of 28 days to 90 days duration, done in rats and mice
Examples
Repeated Dose 28‐day Oral Toxicity Study in Rodents (TG407)
Repeated Dose 90‐Day Oral Toxicity Study in Rodents (TG 408)
Repeated Dose Dermal Toxicity: 21/28‐day Study (TG 410)
Subchronic Dermal Toxicity: 90‐day Study (TG 411)
Repeated Dose Inhalation Toxicity: 28‐day or 14‐day Study (TG 412)
Subchronic Inhalation Toxicity: 90‐day Study (TG 413)
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Table continued

Type of Study and Description
Chronic Toxicity
• To examine the cardiovascular, respiratory and CNS effects of the study drug.
Various specific tests include:
Cardiovascular
• Dog telemetry
• hERG assay
• isolated Purkinje nerve fibers assays
Respiratory
• Evaluation of the "respiratory pump" efficiency and gas exchange
• Whole body plethysmography - to evaluate parameters including tidal
volume, minute volume and mid-expiratory flow (EF50)
CNS
• To observed compound effects on general behavior, locomotion,
neuromuscular coordination, seizure threshold, and vigilance through
functional observation battery and Irwin test
Genotoxicity
• These tests identify compounds that can induce genetic damage
• These are mostly required for small molecules, but not generally required for
biologics
Standard battery of tests include:
• Bacterial reverse gene mutation test
• In vitro chromosomal aberrations using Ames test
• In in vitro mammalian cells using the following:
o In vitro metaphase chromosome aberration assay
o In vitro micronucleus assay
o mouse lymphoma L5178Y cell Tk gene mutation assay
• In in vivo test using rodent hematopoietic cells, either for micronuclei or for
chromosomal aberrations in metaphase cells
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Table continued

Type of Study and Description
Developmental and Reproductive Toxicity
• Teratogenecity
Embryonic and fetal tests are usually performed in two or three species (rats,
mice, rabbits) by administering drug to females in the initial period of pregnancy (in
rats, 6–16 days after mating).
• Male and Female fertility
Fertility and implantation tests include male (28 days) and female (14 days)
treatments with the substance before mating, and are characterized by the semen
analysis (counting and viability), number of implanted embryos and survival of the
embryos at the sixth day of pregnancy
• Pre-/post-natal development
In these tests, females are treated during pregnancy and lactation. Post-lactation
motor activity, any abnormalities in different stages of development, their sexual
performance and second offspring among the pups are studied
Carcinogenicity
• To assess the risk of cancer induction by the chemical in exposed humans
•

Incidence and type of the tumors that develop in rats and mice when dosed for
up to two years (the typical lifespan)

Note. CNS, central nervous system; OECDTG, Organisation for Economic Co-operation and Development Test
Guidelines; hERG, human ether-a-go-go-related gene.
From “Non-clinical studies in the process of new drug development: Part II: Good laboratory practice,
metabolism, pharmacokinetics, safety and dose translation to clinical studies” by E. L. Andrade, A. F. Bento,
J.Cavalli, S. K. Oliveira, R. C. Schwanke, J. M. Siqueira, C. S. Freitas, R. Marcon, and J. B. Calixto, 2016,
Brazilian Journal of Medical and Biological Research, 49, p7–17;
“Chapter 9: Animal use in toxicity studies”, The ethics of research involving animals. p. 155–167. London:
Nuffield Council on Bioethics.
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Appendix B: Questionnaire
1)

Position at FDA
a.

Reviewing Pharmacologist

b.

Supervisory Pharmacologist

c.

Other

2)

Review Center
a.

CDER

b.

CBER

c.

Other

3)

Years at FDA
a.

0 to 2

b.

2 to 5

c.

6 to 10

d.

Greater than 10
Are you willing/able to provide informal advice to sponsors prior to
submission of an IND

4)
a.

Yes

b.

Yes, but time is extremely limited

c.

Yes, but a pre-IND meeting request and supporting documentation must be
submitted

d.

No, an active IND must be on file

5)

The best way to obtain advice prior to IND submission is via
a.

Teleconference to discuss previously submitted materials

b.

Face-to-face meeting to discuss previously submitted materials

c.

Email replies from a project manager to very specific questions

d.

Email replies from a reviewer to very specific questions
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6)

50

The appropriate contact to request pre-IND advice is
a.

The supervisory project manager

b.

Any divisional project manager

c.

The division director

d.

Directly to a reviewing or supervisory pharmacologist

7)

Synthetic peptides should be considered, for genotoxicity purposes,
a.

To be handled like small molecules

b.

To be handled like a biologic product

c.

To vary by compound. Pre-testing consultation should be sought.

d.

Unknown
If human synthetic peptides or biologics do not show the same
pharmacology in animal models as they do in human tissue cultures, it this
a concern for selection of species for toxicology testing?

8)
a.

No. Rodent and non-rodent studies should be conducted as usual

b.

No, as long as dose-limiting toxicity is above the expected human therapeutic
dose

c.

Yes, the animal model used for toxicity testing must exhibit the same
pharmacology as that expected in humans

d.

Pre-testing consultation with the Review Division should be sought.
If pre-testing consultation is required before beginning toxicology tests, how
much time should the sponsor build into their planning to allow
appropriate input from the agency?

9)
a.

1 to 2 weeks

b.

1 month

c.

2 months

d.

More than 2 months
Have you had personal experience dealing with issues like those mentioned
in this survey.

10)
a.

Yes for issues pre-IND, but not those specific ones mentioned here.
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b.

Yes

c.

No
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